Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ansell

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
BJS Open|February 1, 2021
Variation in training requirements within general surgery: comparison of 23 countriesH Whewell, C Brown, V J Gokani, et al.
Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
BJS Open|February 1, 2021
Variation in training requirements within general surgery: comparison of 23 countriesH Whewell, C Brown, V J Gokani, et al.
Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Pageof 20